USPTO Examiner CHONG KIMBERLY - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18797394TREATMENT OF MST1 RELATED DISEASES AND DISORDERSAugust 2024March 2025Allow711NoNo
18594132COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFMarch 2024October 2024Allow820NoNo
18410136NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERYJanuary 2024May 2024Allow410NoNo
18543966COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOFDecember 2023February 2025Abandon1421NoNo
18449850TARGETED TRANS-SPLICING USING CRISPR/CAS13August 2023January 2025Allow1722YesNo
18178841Oligonucleotide Comprising Inosine for Treating DMDMarch 2023May 2025Abandon2601NoNo
18174793METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASEFebruary 2023May 2025Abandon2710NoNo
18147549REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPYDecember 2022June 2025Abandon3010NoNo
18145604ANTISENSE OLIGOMER COMPOUNDSDecember 2022April 2025Abandon2710NoNo
18086209SIRT1-saRNA Compositions and Methods of UseDecember 2022June 2025Abandon3001NoNo
18056664COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHYNovember 2022December 2024Allow2520NoNo
18056382Nucleic Acid Compounds for Binding Growth Differentiation Factor 11November 2022May 2025Abandon2901NoNo
18053447Modulators of APOL1 ExpressionNovember 2022August 2024Allow2110NoNo
18047973COMPOUNDS AND METHODS FOR MODULATING ATXN1October 2022August 2024Allow2210NoNo
17936820MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROMESeptember 2022June 2025Allow3221NoNo
17931659Novel System for the Biocontrol of White Spot Syndrome Virus (WSSV) in AquacultureSeptember 2022July 2024Allow2210NoNo
17822511LYOPHILIZATION OF RNAAugust 2022September 2024Allow2411NoNo
17818879STABILIZED HNF4A SARNA COMPOSITIONS AND METHODS OF USEAugust 2022May 2025Abandon3311NoNo
17815493ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOFJuly 2022August 2024Allow2410NoNo
17867929METHODS RELATING TO LUNG CANCERJuly 2022April 2025Allow3221YesYes
17813249Modulation of Huntingtin ExpressionJuly 2022January 2025Allow3021NoNo
17811808DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNAJuly 2022September 2024Allow2611NoNo
17810495CIRCULATING MICRORNA SIGNATURES FOR OVARIAN CANCERJuly 2022April 2025Allow3321YesNo
17842478OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITYJune 2022January 2025Allow3121NoNo
17840152CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASJune 2022March 2025Abandon3321NoNo
17743663Modified RNA Agents with Reduced Off-Target EffectMay 2022October 2024Allow2921NoNo
17738987METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONSMay 2022July 2024Allow2611NoNo
17721530COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFApril 2022March 2025Allow3511NoNo
17697577Modified Compounds and Uses ThereofMarch 2022September 2024Allow3011NoNo
17693120TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTRMarch 2022August 2024Allow3020NoNo
17676586DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNAFebruary 2022March 2024Allow2510YesNo
17675800TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERSFebruary 2022July 2024Allow2911YesNo
17667094MODULATORS OF MALAT1 EXPRESSIONFebruary 2022August 2024Allow3021NoNo
17665348COMPOUNDS AND METHODS FOR MODULATING C90RF72February 2022January 2025Abandon3511NoNo
17581855OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSIONJanuary 2022March 2024Allow2611NoNo
17576245Compounds and Methods for Modulating UBE3A-ATSJanuary 2022June 2024Allow2911NoNo
17537195BI SPECIFIC APTAMERNovember 2021July 2024Allow3221NoNo
17524323NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELLNovember 2021June 2025Abandon4311YesNo
17523030CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021April 2025Allow4122YesNo
17498880ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODSOctober 2021June 2024Allow3211NoNo
17478219THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETSSeptember 2021July 2024Allow3421NoNo
17474765CONJUGATION OF LIPOPHILIC ALBUMIN-BINDING MOIETY TO RNA FOR IMPROVED CARRIER-FREE IN VIVO PHARMACOKINETICS AND GENE SILENCINGSeptember 2021September 2024Allow3621NoNo
17436254MULTIMERIC OLIGONUCLEOTIDES WITH ENHANCED BIOACTIVITYSeptember 2021January 2025Abandon4011YesNo
17411460Treatment Of Sepsis With PCSK9 And LDLR ModulatorsAugust 2021March 2025Allow4311YesNo
17305225MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCEJuly 2021December 2024Allow4131NoNo
17364765NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOFJune 2021March 2025Allow4541NoNo
17323826METHODS FOR REDUCING ATAXIN-2 EXPRESSIONMay 2021August 2024Allow3921YesNo
17320139OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULINMay 2021September 2024Allow4042YesNo
17284310DETECTING CANCER CELL OF ORIGINApril 2021March 2025Abandon4711NoNo
17204483OLIGONUCLEOTIDES FOR SNCA MODULATIONMarch 2021March 2024Allow3621NoYes
17271496COMPOSITIONS AND METHODS FOR DETECTING ANTIBIOTIC RESPONSIVE mRNA EXPRESSION SIGNATURES AND USES THEREOFFebruary 2021June 2025Allow5221NoNo
17181870MULTI-TARGETED SINGLE ENTITY CONJUGATESFebruary 2021September 2024Allow4331YesNo
16982758BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACIDFebruary 2021January 2025Allow5221YesNo
17144456EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATIONJanuary 2021August 2024Allow4321NoNo
17129463PLANT VIRAL RNA DELIVERY NANOPARTICLES AND USES THEREOFDecember 2020September 2024Allow4541NoNo
17055710MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECTNovember 2020September 2024Allow4511NoNo
17054724OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDESNovember 2020December 2024Abandon4922NoNo
17090804DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE - IINovember 2020June 2025Allow5531NoNo
16772678COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOFSeptember 2020March 2025Allow5721YesNo
16967131HETEROCHIRAL NUCLEIC ACID STRAND-DISPLACEMENT SYSTEMS AND METHODSAugust 2020October 2024Allow5111NoNo
16961187COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLSJuly 2020August 2024Allow4911NoNo
16955596DOUBLE-STRANDED DNA MOLECULE FOR THE DETECTING AND CHARACTERIZING MOLECULAR INTERACTIONSJune 2020July 2025Allow6031YesNo
16875257ENGINEERED POST-POLY A SIGNAL RNA AND USES THEREOFMay 2020August 2024Allow5121YesNo
16827454METHODS OF TREATING DANON DISEASEMarch 2020June 2023Allow3931YesNo
16638107CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHYFebruary 2020June 2025Allow6031NoNo
16665985MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASEOctober 2019January 2025Abandon6011NoNo
16333185PROXIMITY-DEPENDENT BIOTINYLATION AND USES THEREOFMarch 2019September 2024Allow6051YesNo
16089190CONSTRUCTION OF MICRORNA GENE-MEDIATED NOVEL TISSUE ENGINEERED NERVE AND APPLICATIONS THEREOF IN REPAIRING NERVE DEFECTSeptember 2018January 2020Allow1611NoNo
16046389ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELDJuly 2018December 2019Allow1710NoNo
15928494Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical FieldMarch 2018March 2020Allow2400NoNo
15746570METHOD FOR MEASURING IN VIVO INHIBITION OF INTRACELLULAR RNASEJanuary 2018March 2020Allow2621YesNo
15834110METHODS OF TREATING CANCERDecember 2017September 2018Allow911NoNo
15705631IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENTSeptember 2017July 2019Allow2211NoNo
15527568MITOCHONDRIAL PHOSPHATE CARRIER TARGETS FOR TREATING SOFT-TISSUE CALCIFICATIONMay 2017September 2018Allow1611NoNo
15586581FACTOR XIA-SPECIFIC APTAMERSMay 2017July 2019Allow2721NoNo
15519468METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDEApril 2017February 2019Allow2211NoNo
15479879FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTSApril 2017May 2019Allow2621NoNo
15451716Method For Affinity PurificationMarch 2017October 2018Allow2011NoNo
15433400DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOFFebruary 2017July 2019Allow2921NoNo
15265813TREATMENT FOR CONDITIONS ASSOCIATED WITH FIBROSIS AND COLLAGEN DEPOSITIONSeptember 2016June 2018Allow2121YesNo
15027216Compositions and Methods for Treating Cancer with JAK2 ActivityApril 2016July 2018Allow2721NoNo
14996493Double Stranded Oligonucleotide Compounds Comprising Positional ModificationsJanuary 2016June 2018Allow2911NoNo
14767113DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTSAugust 2015April 2019Allow4431NoNo
14688499NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERSApril 2015June 2018Allow3861YesNo
13595204MicroRNA Fingerprints During Human MegakaryocytopoiesisAugust 2012March 2013Allow711NoNo
13595207MicroRNA Fingerprints During Human MegakaryocytopoiesisAugust 2012March 2013Allow611NoNo
13595200MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESISAugust 2012March 2013Allow711NoNo
13540413METHOD AND COMPOSITIONS INVOLVING MICRORNAJuly 2012April 2013Allow910NoNo
13531087MODULATION OF FORKHEAD BOX O1A EXPRESSIONJune 2012July 2013Allow1320NoNo
13499005COMPOSITION FOR TREATMENT OF PANCREATIC CANCERJune 2012June 2013Allow1411YesNo
13477825OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1A EXPRESSIONMay 2012September 2012Allow400NoNo
13365676SYNTHETIC MIMICS OF MIR-34February 2012August 2013Allow1911YesNo
13380320COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY DISORDERS AND FIBROTIC DISEASEJanuary 2012March 2013Allow1511YesNo
13345893ANTI-MICRORNA OLIGONUCLEOTIDE MOLECULESJanuary 2012July 2012Allow600NoNo
13213390REDUCING IRF4, DUSP22, OR FLJ43663 POLYPEPTIDE EXPRESSIONAugust 2011November 2012Allow1530NoNo
13136812siRNA targeting myeloid differentiation primary response gene (88) (MYD88)August 2011December 2012Allow1611NoNo
13169184MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESISJune 2011February 2012Allow700NoNo
13139280PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER AND ASTHMAJune 2011November 2012Allow1721NoNo
13121137OLIGONUCLEOTIDIC SEQUENCES ABLE TO SILENCE THE EXPRESSION OF THE CYCLIN D1-TROP2 CHIMERA AND USES THEREOF IN MEDICAL FIELDMay 2011April 2013Allow2421NoNo
13082790Methods to enhance T-cell mediated immune responseApril 2011November 2013Allow3121NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, KIMBERLY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
2
(33.3%)
Examiner Reversed
4
(66.7%)
Reversal Percentile
85.3%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
26
Allowed After Appeal Filing
10
(38.5%)
Not Allowed After Appeal Filing
16
(61.5%)
Filing Benefit Percentile
60.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHONG, KIMBERLY - Prosecution Strategy Guide

Executive Summary

Examiner CHONG, KIMBERLY works in Art Unit 1636 and has examined 232 patent applications in our dataset. With an allowance rate of 92.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner CHONG, KIMBERLY's allowance rate of 92.7% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHONG, KIMBERLY receive 2.29 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHONG, KIMBERLY is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +8.4% benefit to allowance rate for applications examined by CHONG, KIMBERLY. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.3% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 61.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.8% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.